Table 1.
Predicted duration ensuring 95% of women have HPV-16 and -18 antibody titers above antibody titers after natural infection. ELISA: enzyme-linked immunosorbent assay; EU: ELISA unit; GMT: geometric mean titer; HPV: human papillomavirus.
| Antigen | Antibody level at natural infection (EU/mL) |
Model | Population GMTs at 50 years post vaccination (EU/mL) | Predicted time for antibody levels above natural infection in 95% participants (years) |
|---|---|---|---|---|
| HPV-16 | 29.8 | Piecewise | 111.2 | 70.1 |
| Modified power-law | 1,493.9 | Always | ||
| HPV-18 | 22.7 | Piecewise | 90.3 | 78.8 |
| Modified power-law | 555.4 | Always |